What We Do       Leadership       Therapeutic Areas       Partnering       News       Contact

m8 Pharmaceuticals and Gennisium Pharma announce an exclusive License and Distribution Agreement of an orphan hybrid drug for the treatment and prevention of apnea of premature newborns in Mexico and Brazil

April 28th, 2020

 

   Through this agreement, moksha8 strengthens its respiratory portfolio and entry into the Neonatology area.

 

   Gennisium Pharma expands its presence in the most important markets in Latin America: Mexico and Brazil

 

April 28th, 2020.- The US Pharmaceutical Company m8 Pharmaceuticals and the French Corporation Gennisium Pharma today jointly announced that they have entered into an exclusive agreement under which m8 has the exclusive rights to register and commercialize a more suitable formulation of an already existing orphan drug for apnea in Mexico and Brazil, actually the most commonly used medication for treatment and prevention of apnea of prematurity (AOP). Additional pipeline products for the treatment of conditions prevalent in premature newborn patients are also included in this partnership.

 

Apnea of prematurity (AOP) is a condition in which premature infants, born before 34 weeks of gestational age, stop breathing for 15 to 20 seconds and can be accompanied by hypoxia or bradycardia in serious episodes. The incidence of AOP is inversely correlated with gestational age and birth weight: seven percent of neonates born at 34 to 35 weeks gestation, 15% at 32 to 33 weeks, 54% at 30 to 31 weeks, and nearly all infants born at less than 29 weeks gestation or 1,000 grams exhibit AOP.

 

According to World Health Organization, an estimated 15 million babies are born too early every year, that is more than 1 in 10 babies. The in-utero development is disrupted for premature newborns, giving birth to infants with immature organs. Most of these immaturities involve some complications which are often interrelated, and this situation impacts the growth, maturation and ultimately healthy development of preterm infants.

 

Most proposed therapeutic solutions stem from adults treatments and are often not suitable to this vulnerable patient population. Specific treatments and prophylactic therapies for neonates are underdeveloped by the pharmaceutical industry, making important to provide and expand medications that responds to critical health needs of preterm infants.

 

This agreement is aligned with both companies‘strategic imperatives and they shall begin working together with immediate effect to bring these solutions to Latin American patients.

 

Joel Barlan, m8’s CEO, said: “We are delighted to be working with Gennisium Pharma. This new partnership represents a significant addition to our portfolio and within our strategy; in one way, it will allow us to strengthen our Orphan Drug portfolio and further consolidate our presence in Neonatology area, thus bringing benefits to other sectors of the population. By working with Gennisium Pharma we will be able to demonstrate our ability to leverage the knowledge and our unique expertise to establish and make grow leading products. Also, it will help to advance our mission of improve the lives of patients with more access to better treatments, specifically in Brazil, one of the 10 countries with the greatest number of preterm births”. Furthermore, Franck Pigache, Gennisium Pharma’s CEO mentioned: “We are very pleased to have signed this licensing agreement with m8, a successful company with several years of experience in registering and marketing medicines on niche and orphan drugs in Brazil and Mexico. We intend to build up a dedicated business for neonatology and prematurity therapeutic area from m8 within these countries. Our first product should be approved by European Health Agency (EMA) by the end of the year in AOP and the current exclusive agreement reflects our willingness to expand our presence outside Europe with key partners”.

 

The partnership represents the opportunity for further collaboration between companies and constitutes a solid pillar for their growth strategy.

 

About GENNISIUM PHARMA

Gennisium Pharma is a French pharmaceutical company based in Paris and specialized in development, registration and commercialization of special medicines for Neonatology with global reach. Our mission is to provide health care professionals and neonatal intensive care units with novel and suitable formulations of medicines needed to prevent or treat neonatal diseases and conditions. About M8 PHARMACEUTICALS

m8 is a specialty pharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in the two largest Latin America markets: Brazil and Mexico. m8 is a Montreux Equity Partners portfolio company.

 

About MONTREUX

Montreux Equity Partners is a private investment firm focused on making growth capital investments in the leading companies of tomorrow. Its portfolio companies address the most compelling trends in global health. The firm is currently investing out of its sixth fund.

 

For more information please contact:

 

m8 Pharmaceuticals Inc,

Joel Barlan

Chief Executive Officer

T: +52 (55) 4431 2933

us.wm@moksha8.com

 

Rafael Ferrer

Vice President of Corporate Development

T: +1 (305) 299 6998

rafael.ferrer@moksha8.com

Gennisium Pharma

Frank Pigache

Chief Executive Officer

T: +33 6 24 43 62 98

fpigache@gennisium.com

  •  
  •  

COPYRIGHT © 2006-2020 MOKSHA8 PHARMACEUTICALS, INC. ALL RIGHTS RESERVED. THIS INFORMATION—INCLUDING PRODUCT INFORMATION—IS INTENDED ONLY FOR RESIDENTS OF THE UNITED STATES. THE PRODUCTS DISCUSSED HEREIN MAY HAVE DIFFERENT LABELING IN DIFFERENT COUNTRIES.

 

PRIVACY POLICY | LEGAL DISCLAIMER | LINKEDIN | ENGLISH | PORTUGUESE | SPANISH

moksha8 Mexico will commercialize Duaklir and Eklira, the Astra Zeneca treatments indicated for Chronic Obstructive Pulmonary Disease

December 11th 2018

 

moksha8 Mexico and Astra Zeneca, a leading pharmaceutical company in respiratory therapies, have signed an agreement under which moksha8 Mexico will assume responsibility for promoting and distributing Duaklir and Eklira (aclidinium bromide/formoterol fumarate dihydrate 400/12 μg) in the Mexican territory. Duaklir and Eklira are indicated for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

 

COPD is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 300 million people worldwide and is predicted to be the third leading cause of death by 2030*.

 

The PLATINO study described the epidemiology of COPD in five major Latin American cities. This population-based study reported crude prevalence rates of COPD of 7.8% in Mexico City**.

 

Approximately 90 per cent of COPD patients experience symptoms such as breathlessness and coughing during at least one part of the day and Eklira /Duaklir provides patients with a safe, effective way to improve breathlessness and lung function to these patients.

 

Joel Barlan, moksha8 CEO said: “This strategic partnership will strengthen our pharmaceutical business, accelerating the build of our pipeline and our presence in the respiratory area. Also, we are pleased to continue providing such excellent products for all COPD patients in Mexico.”

 

This agreement represents an immediate opportunity for moksha 8 to build its respiratory portfolio and presence, and these products will add new revenue growth.

*World Health Organization. Burden of COPD.

**Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875–1881

 

 

Montreux Partners Portfolio Company Moksha8 Announces The Appointment Of Mariano Garcia-Valiño To Its Board Of Directors

Berwin, Pennsylvania, USA, December 10th 2018

 

moksha8, a specialty pharmaceutical company, announces the appointment of Mariano Garcia-Valiño as a Board Member and Chairman of its Compensation and Business Development Committees.

 

Mariano has been active at the intersection of healthcare, deal-making and entrepreneurship for over 25 years, experiencing the space from many different angles, be it by building and operating companies, leading M&A and licensing transactions, working for some of the premier players in the business or managing investments for professional equity firms.

 

Recently, Mariano stepped down as CEO of Biotoscana Investments (BR:GBIO33), a company he architected, launched and took public in a transaction that was the largest healthcare IPO in the Americas in 2017 and the region’s first cross-border IPO in a decade.   Under his leadership, the company acquired, merged and transformed several local pharmaceutical players into a streamlined 10-country leading specialty player and closed licensing deals for over 40 novel compounds with some of the premier players in the world.

 

“We are very excited to have Mariano join our Board”, said Daniel K. Turner III, Founding Partner of Montreux.  “He brings invaluable experience in building Latin-American platforms and a unique track record in licensing and M&A. We believe he will be instrumental in taking Moksha8 to the next level”.

 

“I am very excited to work with the team at Montreux and Moksha8, whom I have known for several years and with whom we share a passion for building great businesses”, said Mr. Garcia-Valiño.   “Mariano is joining at a pivotal time”, added Joel Barlan, CEO of Moksha8.  “The company is leaving its start-up phase and prepared for accelerated development.   We believe Moksha8 will benefit highly from his experience”.

 

Mr. Garcia-Valiño holds an Engineering degree from Universidad de Buenos Aires and an MBA from the Harvard Business School.  He is based in Montevideo, Uruguay.

 

moksha8 Pharmaceuticals and CheplaPharm completed a strategic partnership to distribute Questran in Mexico and Brazil

October 31st, 2018

 

moksha8 Pharmaceuticals and the Germany Laboratory, CHEPLAPHARM Arzneimittel GmbH, have signed an agreement in which moksha8 will commercialize and promote Questran in Mexico and Brazil.

 

Questran (Cholestyramine) is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low-density lipoprotein [LDL] cholesterol).

 

High level of cholesterol increases the risks of heart disease and stroke. Globally, a third of ischaemic heart disease is attributable to high cholesterol.  Overall, hypercholesterolemia is estimated to cause 2.6 million deaths. Prevalence High cholesterol among adults is 39% worldwide (37% for males and 40% for females) the highest prevalence according to WHO is Europe (54% for both sexes), followed by the Americas (48% for both sexes).

 

In Latin America, lipid abnormalities have a high prevalence and this is related to multiple causes: genetic load and epigenetic modifications combined with a sedentary lifestyle and an inadequate nutrition*.

 

Questran (Cholestyramine) has proven if is used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks.

 

moksha8 and CheplaPharm have an established great partnership since last year with the distribution agreement for Dilatrend in Mexico and, due to the positive results achieved, the companies decided to expand their commercial relationship in the South American country.

 

With this agreement, moksha8 Pharmaceuticals continues with its global diversification strategy and is increasing its cardiology portfolio. In Mexico, Questran is the second product in the cardiology line and in the case of Brazil, Questran will be the therapy with which the subsidiary will enter into the therapeutic area.

 

moksha8 is committed to work hard to maximize the product value of Questran and further contribute to hypercholesterolemia treatments in the LA region.

 

 

* World Health Organization/cholesterol, 2011

 

 

moksha8 Brazil announces a strategic alliance with HRA Pharma to commercialize Lysodren as the first step to build an Oncology line in this Market

March 26th, 2018

 

moksha8 Brazil has entered into a Promotion and Distribution Agreement with HRA Pharma to commercialize Lysodren in Brazil as the first step to build an Oncology line in this country. Lysodren (mitotane tablets) is an oral chemotherapeutic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma and until now the only product available in the market for this type of cancer.

 

Adrenocortical carcinoma (ACC) is a rare and aggressive tumor which peaks in incidence during the first and fifth decades of life. ACC has an estimated worldwide annual incidence of 2 cases per million overall. The highest reported annual incidence of pediatric ACC in the world occurs in Southern Brazil (3.4 per million) and is 10-15-fold higher compared to the United States (U.S.), where the annual incidence of pediatric ACC is 0.2-0.3 cases per million*.

 

With this alliance and the new addition to its portfolio, moksha8 expects higher revenue growth and this expansion into the Oncology therapeutic area allows it to achieve a greater presence in the markets in which it operates.

 

The deal is also relevant for moksha8 because with it, the company continues its philosophy to bring innovative treatments to improving the health and quality of life to patients around the world, especially with rare and aggressive disease as adrenal cortical carcinoma.

 

HRA Pharm, a fast growing, innovative healthcare company with headquarters in Paris, France, affirmed that this partnership allows them to expand the international reach of its Endocrinology and Rare Disease Division in different markets such as Europe, United States, Canada, Brazil and South Korea and strengthens its position as a key player in Adrenal Cortical Carcinoma.

 

The companies expect strong results and a possible expansion of the relationship in the South America Country.

 

 

*Adrenocortical Carcinoma in Adults and Children: A Population-Based Outcomes Study involving 1,623 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2012)

Remedy Publications LLC   Published 06 May, 2016

 

 

moksha8 Pharmaceuticals and Daewoong Pharmaceuticals sign exclusive licensing agreement to commercialize Nabota (botulinum toxin) in Brazil

January 29, 2018

 

moksha8 Pharmaceuticals, announced today that it has entered into an exclusive licensing agreement with Daewoong Pharmaceuticals to commercialize botulinum toxin product Nabota in Brazil, the largest economy in Latin America.

 

“We are honored to be partnering with Daewoong Pharmaceuticals, one of the leading research- based companies in the world, in order to help expand the usage of Nabota in Latin America", said Joel Barlan.

 

Under the new agreement, moksha8 will be responsible for marketing authorizations, market access, commercialization, distribution throughout Brazil.

 

moksha8 Brazil will adopt a two-track marketing strategy for Nabota, the company will be in charge of Nabota applied to medical conditions while cosmetic use will be taken care of by GC Aesthetic Brazil, the leading pure play female Aesthetic company.

moksha8 Mexico will commercialize Duaklir and Eklira, the Astra Zeneca treatments indicated for Chronic Obstructive Pulmonary Disease

December 11th 2018

 

moksha8 Mexico and Astra Zeneca, a leading pharmaceutical company in respiratory therapies, have signed an agreement under which moksha8 Mexico will assume responsibility for promoting and distributing Duaklir and Eklira (aclidinium bromide/formoterol fumarate dihydrate 400/12 μg) in the Mexican territory. Duaklir and Eklira are indicated for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

 

COPD is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 300 million people worldwide and is predicted to be the third leading cause of death by 2030*.

 

The PLATINO study described the epidemiology of COPD in five major Latin American cities. This population-based study reported crude prevalence rates of COPD of 7.8% in Mexico City**.

 

Approximately 90 per cent of COPD patients experience symptoms such as breathlessness and coughing during at least one part of the day and Eklira /Duaklir provides patients with a safe, effective way to improve breathlessness and lung function to these patients.

 

Joel Barlan, moksha8 CEO said: “This strategic partnership will strengthen our pharmaceutical business, accelerating the build of our pipeline and our presence in the respiratory area. Also, we are pleased to continue providing such excellent products for all COPD patients in Mexico.”

 

This agreement represents an immediate opportunity for moksha 8 to build its respiratory portfolio and presence, and these products will add new revenue growth.

*World Health Organization. Burden of COPD.

**Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875–1881

 

 

Montreux Partners Portfolio Company Moksha8 Announces The Appointment Of Mariano Garcia-Valiño To Its Board Of Directors

Berwin, Pennsylvania, USA, December 10th 2018

 

moksha8, a specialty pharmaceutical company, announces the appointment of Mariano Garcia-Valiño as a Board Member and Chairman of its Compensation and Business Development Committees.

 

Mariano has been active at the intersection of healthcare, deal-making and entrepreneurship for over 25 years, experiencing the space from many different angles, be it by building and operating companies, leading M&A and licensing transactions, working for some of the premier players in the business or managing investments for professional equity firms.

 

Recently, Mariano stepped down as CEO of Biotoscana Investments (BR:GBIO33), a company he architected, launched and took public in a transaction that was the largest healthcare IPO in the Americas in 2017 and the region’s first cross-border IPO in a decade.   Under his leadership, the company acquired, merged and transformed several local pharmaceutical players into a streamlined 10-country leading specialty player and closed licensing deals for over 40 novel compounds with some of the premier players in the world.

 

“We are very excited to have Mariano join our Board”, said Daniel K. Turner III, Founding Partner of Montreux.  “He brings invaluable experience in building Latin-American platforms and a unique track record in licensing and M&A. We believe he will be instrumental in taking Moksha8 to the next level”.

 

“I am very excited to work with the team at Montreux and Moksha8, whom I have known for several years and with whom we share a passion for building great businesses”, said Mr. Garcia-Valiño.   “Mariano is joining at a pivotal time”, added Joel Barlan, CEO of Moksha8.  “The company is leaving its start-up phase and prepared for accelerated development.   We believe Moksha8 will benefit highly from his experience”.

 

Mr. Garcia-Valiño holds an Engineering degree from Universidad de Buenos Aires and an MBA from the Harvard Business School.  He is based in Montevideo, Uruguay.

 

moksha8 Pharmaceuticals and CheplaPharm completed a strategic partnership to distribute Questran in Mexico and Brazil

October 31st, 2018

 

moksha8 Pharmaceuticals and the Germany Laboratory, CHEPLAPHARM Arzneimittel GmbH, have signed an agreement in which moksha8 will commercialize and promote Questran in Mexico and Brazil.

 

Questran (Cholestyramine) is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low-density lipoprotein [LDL] cholesterol).

 

High level of cholesterol increases the risks of heart disease and stroke. Globally, a third of ischaemic heart disease is attributable to high cholesterol.  Overall, hypercholesterolemia is estimated to cause 2.6 million deaths. Prevalence High cholesterol among adults is 39% worldwide (37% for males and 40% for females) the highest prevalence according to WHO is Europe (54% for both sexes), followed by the Americas (48% for both sexes).

 

In Latin America, lipid abnormalities have a high prevalence and this is related to multiple causes: genetic load and epigenetic modifications combined with a sedentary lifestyle and an inadequate nutrition*.

 

Questran (Cholestyramine) has proven if is used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks.

 

moksha8 and CheplaPharm have an established great partnership since last year with the distribution agreement for Dilatrend in Mexico and, due to the positive results achieved, the companies decided to expand their commercial relationship in the South American country.

 

With this agreement, moksha8 Pharmaceuticals continues with its global diversification strategy and is increasing its cardiology portfolio. In Mexico, Questran is the second product in the cardiology line and in the case of Brazil, Questran will be the therapy with which the subsidiary will enter into the therapeutic area.

 

moksha8 is committed to work hard to maximize the product value of Questran and further contribute to hypercholesterolemia treatments in the LA region.

 

 

* World Health Organization/cholesterol, 2011

 

 

moksha8 Brazil announces a strategic alliance with HRA Pharma to commercialize Lysodren as the first step to build an Oncology line in this Market

March 26th, 2018

 

moksha8 Brazil has entered into a Promotion and Distribution Agreement with HRA Pharma to commercialize Lysodren in Brazil as the first step to build an Oncology line in this country. Lysodren (mitotane tablets) is an oral chemotherapeutic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma and until now the only product available in the market for this type of cancer.

 

Adrenocortical carcinoma (ACC) is a rare and aggressive tumor which peaks in incidence during the first and fifth decades of life. ACC has an estimated worldwide annual incidence of 2 cases per million overall. The highest reported annual incidence of pediatric ACC in the world occurs in Southern Brazil (3.4 per million) and is 10-15-fold higher compared to the United States (U.S.), where the annual incidence of pediatric ACC is 0.2-0.3 cases per million*.

 

With this alliance and the new addition to its portfolio, moksha8 expects higher revenue growth and this expansion into the Oncology therapeutic area allows it to achieve a greater presence in the markets in which it operates.

 

The deal is also relevant for moksha8 because with it, the company continues its philosophy to bring innovative treatments to improving the health and quality of life to patients around the world, especially with rare and aggressive disease as adrenal cortical carcinoma.

 

HRA Pharm, a fast growing, innovative healthcare company with headquarters in Paris, France, affirmed that this partnership allows them to expand the international reach of its Endocrinology and Rare Disease Division in different markets such as Europe, United States, Canada, Brazil and South Korea and strengthens its position as a key player in Adrenal Cortical Carcinoma.

 

The companies expect strong results and a possible expansion of the relationship in the South America Country.

 

 

*Adrenocortical Carcinoma in Adults and Children: A Population-Based Outcomes Study involving 1,623 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2012)

Remedy Publications LLC   Published 06 May, 2016

 

 

moksha8 Pharmaceuticals and Daewoong Pharmaceuticals sign exclusive licensing agreement to commercialize Nabota (botulinum toxin) in Brazil

January 29, 2018

 

moksha8 Pharmaceuticals, announced today that it has entered into an exclusive licensing agreement with Daewoong Pharmaceuticals to commercialize botulinum toxin product Nabota in Brazil, the largest economy in Latin America.

 

“We are honored to be partnering with Daewoong Pharmaceuticals, one of the leading research- based companies in the world, in order to help expand the usage of Nabota in Latin America", said Joel Barlan.

 

Under the new agreement, moksha8 will be responsible for marketing authorizations, market access, commercialization, distribution throughout Brazil.

 

moksha8 Brazil will adopt a two-track marketing strategy for Nabota, the company will be in charge of Nabota applied to medical conditions while cosmetic use will be taken care of by GC Aesthetic Brazil, the leading pure play female Aesthetic company.

moksha8 Mexico will commercialize Duaklir and Eklira, the Astra Zeneca treatments indicated for Chronic Obstructive Pulmonary Disease

December 11th 2018

 

moksha8 Mexico and Astra Zeneca, a leading pharmaceutical company in respiratory therapies, have signed an agreement under which moksha8 Mexico will assume responsibility for promoting and distributing Duaklir and Eklira (aclidinium bromide/formoterol fumarate dihydrate 400/12 μg) in the Mexican territory. Duaklir and Eklira are indicated for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

 

COPD is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 300 million people worldwide and is predicted to be the third leading cause of death by 2030*.

 

The PLATINO study described the epidemiology of COPD in five major Latin American cities. This population-based study reported crude prevalence rates of COPD of 7.8% in Mexico City**.

 

Approximately 90 per cent of COPD patients experience symptoms such as breathlessness and coughing during at least one part of the day and Eklira /Duaklir provides patients with a safe, effective way to improve breathlessness and lung function to these patients.

 

Joel Barlan, moksha8 CEO said: “This strategic partnership will strengthen our pharmaceutical business, accelerating the build of our pipeline and our presence in the respiratory area. Also, we are pleased to continue providing such excellent products for all COPD patients in Mexico.”

 

This agreement represents an immediate opportunity for moksha 8 to build its respiratory portfolio and presence, and these products will add new revenue growth.

*World Health Organization. Burden of COPD.

**Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875–1881

 

 

Montreux Partners Portfolio Company Moksha8 Announces The Appointment Of Mariano Garcia-Valiño To Its Board Of Directors

Berwin, Pennsylvania, USA, December 10th 2018

 

moksha8, a specialty pharmaceutical company, announces the appointment of Mariano Garcia-Valiño as a Board Member and Chairman of its Compensation and Business Development Committees.

 

Mariano has been active at the intersection of healthcare, deal-making and entrepreneurship for over 25 years, experiencing the space from many different angles, be it by building and operating companies, leading M&A and licensing transactions, working for some of the premier players in the business or managing investments for professional equity firms.

 

Recently, Mariano stepped down as CEO of Biotoscana Investments (BR:GBIO33), a company he architected, launched and took public in a transaction that was the largest healthcare IPO in the Americas in 2017 and the region’s first cross-border IPO in a decade.   Under his leadership, the company acquired, merged and transformed several local pharmaceutical players into a streamlined 10-country leading specialty player and closed licensing deals for over 40 novel compounds with some of the premier players in the world.

 

“We are very excited to have Mariano join our Board”, said Daniel K. Turner III, Founding Partner of Montreux.  “He brings invaluable experience in building Latin-American platforms and a unique track record in licensing and M&A. We believe he will be instrumental in taking Moksha8 to the next level”.

 

“I am very excited to work with the team at Montreux and Moksha8, whom I have known for several years and with whom we share a passion for building great businesses”, said Mr. Garcia-Valiño.   “Mariano is joining at a pivotal time”, added Joel Barlan, CEO of Moksha8.  “The company is leaving its start-up phase and prepared for accelerated development.   We believe Moksha8 will benefit highly from his experience”.

 

Mr. Garcia-Valiño holds an Engineering degree from Universidad de Buenos Aires and an MBA from the Harvard Business School.  He is based in Montevideo, Uruguay.

 

moksha8 Pharmaceuticals and CheplaPharm completed a strategic partnership to distribute Questran in Mexico and Brazil

October 31st, 2018

 

moksha8 Pharmaceuticals and the Germany Laboratory, CHEPLAPHARM Arzneimittel GmbH, have signed an agreement in which moksha8 will commercialize and promote Questran in Mexico and Brazil.

 

Questran (Cholestyramine) is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low-density lipoprotein [LDL] cholesterol).

 

High level of cholesterol increases the risks of heart disease and stroke. Globally, a third of ischaemic heart disease is attributable to high cholesterol.  Overall, hypercholesterolemia is estimated to cause 2.6 million deaths. Prevalence High cholesterol among adults is 39% worldwide (37% for males and 40% for females) the highest prevalence according to WHO is Europe (54% for both sexes), followed by the Americas (48% for both sexes).

 

In Latin America, lipid abnormalities have a high prevalence and this is related to multiple causes: genetic load and epigenetic modifications combined with a sedentary lifestyle and an inadequate nutrition*.

 

Questran (Cholestyramine) has proven if is used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks.

 

moksha8 and CheplaPharm have an established great partnership since last year with the distribution agreement for Dilatrend in Mexico and, due to the positive results achieved, the companies decided to expand their commercial relationship in the South American country.

 

With this agreement, moksha8 Pharmaceuticals continues with its global diversification strategy and is increasing its cardiology portfolio. In Mexico, Questran is the second product in the cardiology line and in the case of Brazil, Questran will be the therapy with which the subsidiary will enter into the therapeutic area.

 

moksha8 is committed to work hard to maximize the product value of Questran and further contribute to hypercholesterolemia treatments in the LA region.

 

 

* World Health Organization/cholesterol, 2011

 

 

moksha8 Brazil announces a strategic alliance with HRA Pharma to commercialize Lysodren as the first step to build an Oncology line in this Market

March 26th, 2018

 

moksha8 Brazil has entered into a Promotion and Distribution Agreement with HRA Pharma to commercialize Lysodren in Brazil as the first step to build an Oncology line in this country. Lysodren (mitotane tablets) is an oral chemotherapeutic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma and until now the only product available in the market for this type of cancer.

 

Adrenocortical carcinoma (ACC) is a rare and aggressive tumor which peaks in incidence during the first and fifth decades of life. ACC has an estimated worldwide annual incidence of 2 cases per million overall. The highest reported annual incidence of pediatric ACC in the world occurs in Southern Brazil (3.4 per million) and is 10-15-fold higher compared to the United States (U.S.), where the annual incidence of pediatric ACC is 0.2-0.3 cases per million*.

 

With this alliance and the new addition to its portfolio, moksha8 expects higher revenue growth and this expansion into the Oncology therapeutic area allows it to achieve a greater presence in the markets in which it operates.

 

The deal is also relevant for moksha8 because with it, the company continues its philosophy to bring innovative treatments to improving the health and quality of life to patients around the world, especially with rare and aggressive disease as adrenal cortical carcinoma.

 

HRA Pharm, a fast growing, innovative healthcare company with headquarters in Paris, France, affirmed that this partnership allows them to expand the international reach of its Endocrinology and Rare Disease Division in different markets such as Europe, United States, Canada, Brazil and South Korea and strengthens its position as a key player in Adrenal Cortical Carcinoma.

 

The companies expect strong results and a possible expansion of the relationship in the South America Country.

 

 

*Adrenocortical Carcinoma in Adults and Children: A Population-Based Outcomes Study involving 1,623 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2012)

Remedy Publications LLC   Published 06 May, 2016

 

 

moksha8 Pharmaceuticals and Daewoong Pharmaceuticals sign exclusive licensing agreement to commercialize Nabota (botulinum toxin) in Brazil

January 29, 2018

 

moksha8 Pharmaceuticals, announced today that it has entered into an exclusive licensing agreement with Daewoong Pharmaceuticals to commercialize botulinum toxin product Nabota in Brazil, the largest economy in Latin America.

 

“We are honored to be partnering with Daewoong Pharmaceuticals, one of the leading research- based companies in the world, in order to help expand the usage of Nabota in Latin America", said Joel Barlan.

 

Under the new agreement, moksha8 will be responsible for marketing authorizations, market access, commercialization, distribution throughout Brazil.

 

moksha8 Brazil will adopt a two-track marketing strategy for Nabota, the company will be in charge of Nabota applied to medical conditions while cosmetic use will be taken care of by GC Aesthetic Brazil, the leading pure play female Aesthetic company.